Journal article
Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma
Abstract
We spotlight the promising preliminary findings reported by Goldsmith et al. of a phase 1 first-in-child study showcasing the safety and efficacy of lorlatinib against treatment-refractory or relapsed ALK-driven neuroblastoma.1.
Authors
Suk Y; Singh SK
Journal
Cell Reports Medicine, Vol. 4, No. 6,
Publisher
Elsevier
Publication Date
June 2023
DOI
10.1016/j.xcrm.2023.101071
ISSN
2666-3791